Travis Perkins market outlook remains weak as Jefferies keeps 'underperform' rating

Impact · against what's priced in

Travis Perkins faces negative pressure as management's bleak outlook for 2026-2027 suggests FY2026 earnings may be under threat, while the lack of M&A potential removes a valuation catalyst. Arecor Therapeutics shows positive progress in its GLP-1 and insulin pipeline, though the impact is speculative based on the provided snippet.

TPK−0.50

No priced-in read yet